Latest news with #JNTC
Korea Herald
14-07-2025
- Business
- Korea Herald
JNTC Unveils Next-Generation Glass Substrate for Semiconductors
Carving Semiconductors into Glass, the Dream Material SEOUL, South Korea, July 14, 2025 /PRNewswire/ -- JNTC Co., Ltd. (KOSDAQ: 204270), a leading advanced materials company, hosted a product launch on June 30 at the Korea Exchange Conference Hall, unveiling its new Through-Glass-Via (TGV) glass substrate under the theme Carving Semiconductors into Glass, the Dream Material.' The event drew more than 200 attendees, including journalists and investors. CEO Andrew Cho introduced the proprietary TGV glass substrate as a breakthrough solution to the limitations of plastic-based substrates. Designed for AI and high-performance computing applications, the substrate offers excellent flatness and thermal stability, which help reduce warpage and heat generation under high-speed processing. JNTC completed its domestic production line in June and expects to begin full-scale manufacturing in August, following test runs in July. Unlike competitors, JNTC built and engineered most of its core production equipment in-house, enabling cost efficiency and full process independence. This approach cut initial investment costs to about one-fifth of the industry average. The newly unveiled substrates support various sizes and thicknesses and feature high-precision via holes (0% microcrack). JNTC also developed its own etching, metalizing (void free), and processing technologies, achieving yields above 90% with minimal defects. Additional packaging features such as alignment marks and cavities have undergone performance verification with global semiconductor leaders. "TGV glass substrates are emerging as critical components in next-gen semiconductor packaging," Cho said. "We have secured a clear edge in quality and cost, and are currently working with 16 global partners across the semiconductor ecosystem. This launch signals our ambition to become a leading global player in precision glass materials." JNTC plans to expand exports and establish a large-scale manufacturing base in Vietnam in the second half of the year, further strengthening its position in the global advanced packaging market.
Yahoo
02-07-2025
- Business
- Yahoo
High Growth Tech Stocks In Asia To Watch This July 2025
As of mid-2025, Asian markets have been buoyed by positive developments such as the U.S. and China finalizing a trade understanding, which has contributed to gains in key indices like the Hang Seng Index and Shanghai Composite Index. In this environment, high growth tech stocks are particularly noteworthy for their potential to capitalize on technological advancements and evolving consumer demands in Asia's dynamic economic landscape. Name Revenue Growth Earnings Growth Growth Rating Suzhou TFC Optical Communication 29.78% 30.32% ★★★★★★ Shengyi Electronics 22.99% 35.16% ★★★★★★ Fositek 28.54% 35.14% ★★★★★★ Range Intelligent Computing Technology Group 27.31% 28.63% ★★★★★★ eWeLLLtd 24.95% 24.40% ★★★★★★ PharmaResearch 24.91% 26.60% ★★★★★★ Global Security Experts 20.56% 28.04% ★★★★★★ Marketingforce Management 26.39% 112.30% ★★★★★★ CARsgen Therapeutics Holdings 81.05% 87.21% ★★★★★★ JNTC 55.45% 94.52% ★★★★★★ Click here to see the full list of 486 stocks from our Asian High Growth Tech and AI Stocks screener. Let's dive into some prime choices out of from the screener. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Wasion Holdings Limited is an investment holding company that focuses on the research, development, production, and sale of energy metering and energy efficiency management solutions for energy supply industries across various regions including China, Africa, the United States, Europe, and Asia; it has a market capitalization of approximately HK$8.36 billion. Operations: Wasion Holdings generates revenue primarily from three segments: Power Advanced Metering Infrastructure (CN¥3.22 billion), Advanced Distribution Operations (CN¥2.90 billion), and Communication and Fluid Advanced Metering Infrastructure (CN¥2.73 billion). The company's operations span across China and multiple international markets, focusing on energy metering and efficiency management solutions for the energy supply industry. Wasion Holdings, a key contender in Asia's tech sector, recently secured significant contracts from the State Grid Corporation of China for smart meters and data collection terminals worth approximately HKD 253.45 million. This achievement underscores its competitive edge in the electronic metering industry, where it outpaced others in total contract value for 2025. Financially, Wasion is on a robust growth trajectory with earnings expected to surge by 23.4% annually, outperforming the Hong Kong market's average of 10.4%. Moreover, its revenue growth at 15.7% annually also surpasses the local market forecast of 8.2%, highlighting its strong market position and potential for sustained growth driven by strategic wins like these recent contracts. Take a closer look at Wasion Holdings' potential here in our health report. Learn about Wasion Holdings' historical performance. Simply Wall St Growth Rating: ★★★★★☆ Overview: Anhui XDLK Microsystem Corporation Limited focuses on the research, development, production, and sale of sensors in China with a market capitalization of CN¥26.83 billion. Operations: Anhui XDLK Microsystem Corporation Limited generates revenue primarily from its Electronic Test & Measurement Instruments segment, amounting to approximately CN¥469.96 million. Anhui XDLK Microsystem has demonstrated a remarkable turnaround in its financial performance, with first-quarter sales soaring to CNY 87.89 million from CNY 22.43 million year-over-year, and net income flipping from a loss of CNY 1.6 million to a profit of CNY 44.37 million. This surge reflects not only robust revenue growth at an annual rate of 34.1% but also significant earnings expansion by 29.2%. The company's strategic focus on innovative microsystem technologies is evidently paying off, positioning it well within Asia's competitive tech landscape despite forecasts suggesting a modest return on equity of 15.4% in three years' time. Click here to discover the nuances of Anhui XDLK Microsystem with our detailed analytical health report. Review our historical performance report to gain insights into Anhui XDLK Microsystem's's past performance. Simply Wall St Growth Rating: ★★★★★☆ Overview: Precision Technology Co., Ltd. specializes in the manufacturing and sale of precision functional and structural parts, with a market capitalization of CN¥5.74 billion. Operations: The company generates revenue primarily from the sale of electronic components and parts, amounting to CN¥795.51 million. With a focus on precision manufacturing, it operates within a market valued at CN¥5.74 billion. Precision Technology has navigated a challenging quarter, with its first-quarter sales slightly increasing to CNY 165.66 million from CNY 162.96 million year-over-year, yet facing a deepened net loss of CNY 11.24 million compared to CNY 5.08 million in the previous year. Despite current unprofitability and high share price volatility, the company is positioned for significant future growth with revenue expected to surge by an impressive 47.2% annually and earnings projected to grow by 80% per year. This growth trajectory is bolstered by strategic initiatives discussed at their recent AGM, such as launching new financial instruments for hedging and optimizing cash management strategies, which could enhance operational efficiencies and financial stability in the coming years. Click here and access our complete health analysis report to understand the dynamics of Precision Technology. Understand Precision Technology's track record by examining our Past report. Explore the 486 names from our Asian High Growth Tech and AI Stocks screener here. Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:3393 SHSE:688582 and SZSE:301326. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-07-2025
- Business
- Yahoo
High Growth Tech Stocks In Asia Baiwang And Two More
As global markets experience a rally with indices like the S&P 500 and Nasdaq Composite hitting all-time highs, Asian tech stocks are drawing attention due to their potential for high growth amidst easing trade tensions and positive economic signals. In this environment, a good stock often demonstrates robust innovation capabilities and adaptability to market changes, making it well-positioned to capitalize on technological advancements and economic shifts. Name Revenue Growth Earnings Growth Growth Rating Suzhou TFC Optical Communication 29.78% 30.32% ★★★★★★ Fositek 28.54% 35.14% ★★★★★★ Shengyi Electronics 22.99% 35.16% ★★★★★★ Range Intelligent Computing Technology Group 27.31% 28.63% ★★★★★★ eWeLLLtd 24.95% 24.40% ★★★★★★ PharmaResearch 24.91% 26.60% ★★★★★★ Global Security Experts 20.56% 28.04% ★★★★★★ Marketingforce Management 26.39% 112.30% ★★★★★★ CARsgen Therapeutics Holdings 81.05% 87.21% ★★★★★★ JNTC 55.45% 94.52% ★★★★★★ Click here to see the full list of 485 stocks from our Asian High Growth Tech and AI Stocks screener. Let's dive into some prime choices out of from the screener. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Baiwang Co., Ltd. offers enterprise digitalization solutions via the Baiwang Cloud platform in China, with a market capitalization of HK$9.59 billion. Operations: Baiwang Co., Ltd. generates revenue primarily from its Internet Software & Services segment, which contributes CN¥659.21 million to its financials. Baiwang, amid recent executive and auditor changes, demonstrates a dynamic corporate environment that could influence its strategic direction. Despite currently being unprofitable, the company is poised for significant growth with revenue expected to increase by 18.7% annually, outpacing the Hong Kong market's 8.2%. This growth trajectory is supported by an impressive forecast of earnings expansion at 112.91% per year. However, it's crucial to note Baiwang's current lack of profitability and negative free cash flow status which may pose challenges in sustaining this rapid growth without effective capital management strategies in place. Navigate through the intricacies of Baiwang with our comprehensive health report here. Gain insights into Baiwang's historical performance by reviewing our past performance report. Simply Wall St Growth Rating: ★★★★★☆ Overview: Sun Create Electronics Co., Ltd is involved in the research and development, design, manufacture, and marketing of radar and security systems with a market capitalization of CN¥8.43 billion. Operations: The company generates revenue primarily from the electronic industry, with reported earnings of CN¥1.56 billion. The focus on radar and security systems forms the core of its business operations. Sun Create Electronics, despite its recent unprofitability, is on a promising trajectory with an expected annual revenue growth of 33.8%, significantly outpacing the Chinese market's 12.4%. This growth is underpinned by a robust forecast in earnings expansion at an impressive rate of 143.3% annually, positioning it well above average market growth projections. The firm's commitment to innovation is evident from its R&D spending trends, which are crucial for maintaining competitive advantage in the fast-evolving tech sector. However, investors should be cautious about its high volatility in share price and recent net losses which decreased from CNY 553.23 million to CNY 245.88 million year-over-year, reflecting some improvement but still posing challenges for future stability and profitability. Delve into the full analysis health report here for a deeper understanding of Sun Create Electronics. Review our historical performance report to gain insights into Sun Create Electronics''s past performance. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Gan & Lee Pharmaceuticals is a biopharmaceutical company focused on the research, development, production, and sale of insulin analog active pharmaceutical ingredients and injections in China with a market capitalization of approximately CN¥33.89 billion. Operations: The company generates revenue primarily from the development, production, and sale of insulin and related products, amounting to approximately CN¥3.47 billion. Gan & Lee Pharmaceuticals has showcased a robust trajectory with its earnings and revenue growth significantly outpacing the industry. Over the past year, earnings surged by 114.7%, dwarfing the biotech sector's decline of 17.7%. This performance is supported by an aggressive R&D investment strategy, crucial in propelling future innovations and maintaining a competitive edge in high-growth markets. The company also demonstrated strong financial health with a net income jump from CNY 96 million to CNY 311.92 million in the latest quarter, reflecting a strategic alignment towards lucrative market segments. Despite these strengths, its projected annual revenue growth of 20% suggests more moderate future expansion compared to some peers, warranting careful monitoring of market position and investment viability moving forward. Get an in-depth perspective on Gan & Lee Pharmaceuticals' performance by reading our health report here. Assess Gan & Lee Pharmaceuticals' past performance with our detailed historical performance reports. Dive into all 485 of the Asian High Growth Tech and AI Stocks we have identified here. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:6657 SHSE:600990 and SHSE:603087. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
01-07-2025
- Business
- Yahoo
High Growth Tech Stocks In Asia Baiwang And Two More
As global markets experience a rally with indices like the S&P 500 and Nasdaq Composite hitting all-time highs, Asian tech stocks are drawing attention due to their potential for high growth amidst easing trade tensions and positive economic signals. In this environment, a good stock often demonstrates robust innovation capabilities and adaptability to market changes, making it well-positioned to capitalize on technological advancements and economic shifts. Name Revenue Growth Earnings Growth Growth Rating Suzhou TFC Optical Communication 29.78% 30.32% ★★★★★★ Fositek 28.54% 35.14% ★★★★★★ Shengyi Electronics 22.99% 35.16% ★★★★★★ Range Intelligent Computing Technology Group 27.31% 28.63% ★★★★★★ eWeLLLtd 24.95% 24.40% ★★★★★★ PharmaResearch 24.91% 26.60% ★★★★★★ Global Security Experts 20.56% 28.04% ★★★★★★ Marketingforce Management 26.39% 112.30% ★★★★★★ CARsgen Therapeutics Holdings 81.05% 87.21% ★★★★★★ JNTC 55.45% 94.52% ★★★★★★ Click here to see the full list of 485 stocks from our Asian High Growth Tech and AI Stocks screener. Let's dive into some prime choices out of from the screener. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Baiwang Co., Ltd. offers enterprise digitalization solutions via the Baiwang Cloud platform in China, with a market capitalization of HK$9.59 billion. Operations: Baiwang Co., Ltd. generates revenue primarily from its Internet Software & Services segment, which contributes CN¥659.21 million to its financials. Baiwang, amid recent executive and auditor changes, demonstrates a dynamic corporate environment that could influence its strategic direction. Despite currently being unprofitable, the company is poised for significant growth with revenue expected to increase by 18.7% annually, outpacing the Hong Kong market's 8.2%. This growth trajectory is supported by an impressive forecast of earnings expansion at 112.91% per year. However, it's crucial to note Baiwang's current lack of profitability and negative free cash flow status which may pose challenges in sustaining this rapid growth without effective capital management strategies in place. Navigate through the intricacies of Baiwang with our comprehensive health report here. Gain insights into Baiwang's historical performance by reviewing our past performance report. Simply Wall St Growth Rating: ★★★★★☆ Overview: Sun Create Electronics Co., Ltd is involved in the research and development, design, manufacture, and marketing of radar and security systems with a market capitalization of CN¥8.43 billion. Operations: The company generates revenue primarily from the electronic industry, with reported earnings of CN¥1.56 billion. The focus on radar and security systems forms the core of its business operations. Sun Create Electronics, despite its recent unprofitability, is on a promising trajectory with an expected annual revenue growth of 33.8%, significantly outpacing the Chinese market's 12.4%. This growth is underpinned by a robust forecast in earnings expansion at an impressive rate of 143.3% annually, positioning it well above average market growth projections. The firm's commitment to innovation is evident from its R&D spending trends, which are crucial for maintaining competitive advantage in the fast-evolving tech sector. However, investors should be cautious about its high volatility in share price and recent net losses which decreased from CNY 553.23 million to CNY 245.88 million year-over-year, reflecting some improvement but still posing challenges for future stability and profitability. Delve into the full analysis health report here for a deeper understanding of Sun Create Electronics. Review our historical performance report to gain insights into Sun Create Electronics''s past performance. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Gan & Lee Pharmaceuticals is a biopharmaceutical company focused on the research, development, production, and sale of insulin analog active pharmaceutical ingredients and injections in China with a market capitalization of approximately CN¥33.89 billion. Operations: The company generates revenue primarily from the development, production, and sale of insulin and related products, amounting to approximately CN¥3.47 billion. Gan & Lee Pharmaceuticals has showcased a robust trajectory with its earnings and revenue growth significantly outpacing the industry. Over the past year, earnings surged by 114.7%, dwarfing the biotech sector's decline of 17.7%. This performance is supported by an aggressive R&D investment strategy, crucial in propelling future innovations and maintaining a competitive edge in high-growth markets. The company also demonstrated strong financial health with a net income jump from CNY 96 million to CNY 311.92 million in the latest quarter, reflecting a strategic alignment towards lucrative market segments. Despite these strengths, its projected annual revenue growth of 20% suggests more moderate future expansion compared to some peers, warranting careful monitoring of market position and investment viability moving forward. Get an in-depth perspective on Gan & Lee Pharmaceuticals' performance by reading our health report here. Assess Gan & Lee Pharmaceuticals' past performance with our detailed historical performance reports. Dive into all 485 of the Asian High Growth Tech and AI Stocks we have identified here. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:6657 SHSE:600990 and SHSE:603087. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
23-06-2025
- Business
- Yahoo
Exploring High Growth Tech Stocks In Asia
As global markets navigate a landscape of mixed economic signals and geopolitical tensions, the Asian tech sector continues to capture attention with its potential for high growth amidst fluctuating indices and shifting interest rates. In such a dynamic environment, identifying promising tech stocks often involves looking at companies that demonstrate strong innovation capabilities, adaptability to market changes, and robust financial health. Name Revenue Growth Earnings Growth Growth Rating Suzhou TFC Optical Communication 29.78% 30.32% ★★★★★★ Shanghai Huace Navigation Technology 24.44% 23.48% ★★★★★★ Fositek 27.37% 35.14% ★★★★★★ Shengyi Electronics 22.99% 35.16% ★★★★★★ Range Intelligent Computing Technology Group 27.31% 28.63% ★★★★★★ PharmaResearch 24.65% 26.40% ★★★★★★ eWeLLLtd 24.95% 24.40% ★★★★★★ Global Security Experts 20.56% 28.04% ★★★★★★ Marketingforce Management 26.39% 112.30% ★★★★★★ JNTC 54.24% 87.93% ★★★★★★ Click here to see the full list of 495 stocks from our Asian High Growth Tech and AI Stocks screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Growth Rating: ★★★★★★ Overview: Dear U Co., Ltd. is an information technology company with a market capitalization of ₩1.37 billion. Operations: The company generates revenue primarily from its Bubble segment, which accounts for ₩72.13 billion. DEAR U Co., LTD. is poised for significant growth with an expected annual revenue increase of 22.6% and earnings growth projected at 37%. This performance outstrips the broader Korean market's growth rates, highlighting its competitive edge in the interactive media and services industry. Despite a challenging past year with earnings contraction of 24.2%, DEAR U's strategic moves, including a notable acquisition by SM Entertainment, underscore its resilience and potential for rebound. The company's robust R&D investment aligns with its ambitious growth targets, ensuring continuous innovation and enhancement of its offerings in a rapidly evolving tech landscape. Delve into the full analysis health report here for a deeper understanding of DEAR U. Assess DEAR U's past performance with our detailed historical performance reports. Simply Wall St Growth Rating: ★★★★★☆ Overview: Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China, with a market capitalization of HK$24.76 billion. Operations: Ascentage Pharma Group International generates revenue primarily from the development and sale of novel small-scale therapies, amounting to CN¥980.65 million. The company is engaged in creating treatments for cancers, chronic hepatitis B virus (HBV), and age-related diseases, focusing on the Mainland China market. Ascentage Pharma Group International is making significant strides in the oncology sector, particularly with its innovative apoptosis-targeted pipeline. The company recently showcased promising clinical data at the ASCO Annual Meeting, highlighting the potential of lisaftoclax and alrizomadlin in treating myeloid malignancies and solid tumors respectively. These developments are pivotal as lisaftoclax has become the first China-developed Bcl-2 inhibitor to reach NDA submission in China, marking a major milestone. Despite a net loss reduction from CNY 925.64 million to CNY 405.43 million year-over-year, Ascentage's commitment to R&D remains robust, positioning it well for future therapeutic advancements and potential market growth. Click here to discover the nuances of Ascentage Pharma Group International with our detailed analytical health report. Gain insights into Ascentage Pharma Group International's historical performance by reviewing our past performance report. Simply Wall St Growth Rating: ★★★★★☆ Overview: Shenzhen SEICHI Technologies Co., Ltd. focuses on the research, development, production, and sale of new display device testing equipment in China with a market capitalization of CN¥7.40 billion. Operations: SEICHI Technologies specializes in developing and manufacturing testing equipment for new display devices, catering to the Chinese market. The company operates with a market capitalization of approximately CN¥7.40 billion, emphasizing its significant presence in the industry. Shenzhen SEICHI Technologies, amidst a robust tech landscape, is navigating through significant financial dynamics. With an annual revenue growth of 30.1%, the company outpaces the CN market average of 12.3%, demonstrating its competitive edge in scaling operations. Despite a recent net loss reported at CNY 16.22 million for Q1 2025, up from CNY 14.44 million the previous year, SEICHI's aggressive R&D investment strategy underscores its commitment to innovation; this is critical as it seeks to reverse negative earnings trends and capitalize on emerging tech opportunities. The firm also repurchased shares worth CNY 21.07 million within March, reflecting confidence in its strategic direction and potential for recovery. Navigate through the intricacies of Shenzhen SEICHI Technologies with our comprehensive health report here. Examine Shenzhen SEICHI Technologies' past performance report to understand how it has performed in the past. Investigate our full lineup of 495 Asian High Growth Tech and AI Stocks right here. Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSDAQ:A376300 SEHK:6855 and SHSE:688627. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
